Corient Private Wealth LLC Purchases 7,653 Shares of Solventum Corporation $SOLV

Corient Private Wealth LLC raised its position in Solventum Corporation (NYSE:SOLV) by 18.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 49,092 shares of the company’s stock after buying an additional 7,653 shares during the period. Corient Private Wealth LLC’s holdings in Solventum were worth $3,859,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Assetmark Inc. raised its stake in shares of Solventum by 21.4% in the fourth quarter. Assetmark Inc. now owns 725 shares of the company’s stock valued at $57,000 after acquiring an additional 128 shares during the last quarter. Hilltop National Bank raised its position in Solventum by 71.3% in the 4th quarter. Hilltop National Bank now owns 310 shares of the company’s stock valued at $25,000 after purchasing an additional 129 shares during the last quarter. Allworth Financial LP boosted its stake in Solventum by 2.8% in the third quarter. Allworth Financial LP now owns 4,788 shares of the company’s stock worth $350,000 after purchasing an additional 129 shares in the last quarter. CIBC Private Wealth Group LLC grew its holdings in shares of Solventum by 0.5% during the third quarter. CIBC Private Wealth Group LLC now owns 24,710 shares of the company’s stock worth $1,804,000 after purchasing an additional 134 shares during the last quarter. Finally, BOKF NA grew its holdings in shares of Solventum by 6.9% during the third quarter. BOKF NA now owns 2,193 shares of the company’s stock worth $160,000 after purchasing an additional 141 shares during the last quarter.

Analysts Set New Price Targets

A number of research firms recently issued reports on SOLV. Piper Sandler cut their price target on Solventum from $98.00 to $92.00 and set an “overweight” rating for the company in a report on Friday, April 17th. Wedbush initiated coverage on shares of Solventum in a research note on Friday, May 15th. They issued an “outperform” rating and a $94.00 target price for the company. Rothschild & Co Redburn started coverage on shares of Solventum in a research report on Tuesday, March 24th. They set a “sell” rating and a $60.00 target price on the stock. Weiss Ratings raised shares of Solventum from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, June 11th. Finally, Wells Fargo & Company dropped their price objective on shares of Solventum from $83.00 to $70.00 and set an “equal weight” rating for the company in a research report on Wednesday, May 6th. Eight equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $84.25.

Solventum Stock Up 2.1%

Solventum stock opened at $79.56 on Friday. The company has a 50 day moving average of $74.58 and a 200-day moving average of $74.62. The company has a quick ratio of 0.75, a current ratio of 1.07 and a debt-to-equity ratio of 0.96. Solventum Corporation has a twelve month low of $62.38 and a twelve month high of $88.20. The stock has a market capitalization of $13.78 billion, a PE ratio of 9.75, a price-to-earnings-growth ratio of 1.20 and a beta of 0.69.

Solventum (NYSE:SOLV) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $1.48 EPS for the quarter, topping analysts’ consensus estimates of $1.35 by $0.13. The business had revenue of $2.01 billion for the quarter, compared to analyst estimates of $1.97 billion. Solventum had a net margin of 17.33% and a return on equity of 23.51%. The firm’s quarterly revenue was down 3.0% on a year-over-year basis. During the same period last year, the business posted $1.34 earnings per share. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. On average, equities research analysts anticipate that Solventum Corporation will post 6.58 EPS for the current fiscal year.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.